



COMMONWEALTH of VIRGINIA
DEPARTMENT OF MEDICAL ASSISTANCE SERVICES

PATRICK W. FINNERTY
DIRECTOR

600 EAST BROAD STREET
SUITE 1300
RICHMOND, VA 23219

November 18, 2009

Dear Pharmaceutical Manufacturer:

The Department of Medical Assistance Services' (DMAS) Pharmacy and Therapeutics Committee will conduct its annual review of Preferred Drug List (PDL) **Phase II** drug classes on February 9, 2010. Existing contracts for PDL Phase II drug classes will end on June 30, 2010 and new contracts will begin on July 1, 2010. DMAS is seeking Virginia-specific contracts for pricing and supplemental rebates directly with manufacturers. Supplemental rebate offers are being solicited for all single-source brand products in the following therapeutic classes:

Analgesics

- ◆ Long Acting Narcotics
- ◆ Non-Steroidal Anti-Inflammatory Drugs (NSAID) (*includes Cox-2 Inhibitors*)

Antibiotics/Anti-infective

- ◆ 2nd and 3rd Generation Cephalosporins
- ◆ 2nd and 3rd Generation Quinolones (systemic)
- ◆ Ketolides
- ◆ Macrolides
- ◆ Oral Antifungals for Onychomycosis
- ◆ Otic Quinolones
- ◆ Topical Antibiotics

Antivirals

- ◆ Herpes Antivirals
- ◆ Influenza Antivirals
- ◆ Topical Antivirals

Asthma- Allergy

- ◆ Intranasal Antihistamines
- ◆ Leukotriene Formation Inhibitors
- ◆ Leukotriene Modifiers

Central Nervous system

- ◆ Antihyperkinesis/CNS Stimulants
- ◆ Non-Ergot Dopamine Receptor Agonists

Dermatologic

- ◆ Benzoyl Peroxide and Clindamycin combinations
- ◆ Topical Agents For Psoriasis
- ◆ Topical Retinoids and combinations

Immunologic agents

- ◆ Multiple Sclerosis Agents
- ◆ Self Administered Drugs For Rheumatoid Arthritis

Ophthalmics

- ◆ Alpha-2 Adrenergic (*for treatment of glaucoma*)
- ◆ Antihistamines
- ◆ Beta-blockers (*for treatment of glaucoma*)
- ◆ Carbonic Anhydrase Inhibitors (*for treatment of glaucoma*)
- ◆ Mast Cell Stabilizers

- ◆ Nonsteroidal Anti-Inflammatory (NSAID)
- ◆ Prostaglandin Analogs (*for treatment of glaucoma*)
- ◆ Quinolones and Macrolides

Oral Hypoglycemics

- ◆ 2nd Generation Sulfonylureas
- ◆ Alpha-Glucosidase Inhibitors
- ◆ Biguanides including combination products
- ◆ DPP-IV Inhibitors and combination products
- ◆ Meglitinides
- ◆ Thiazolidinediones and combination products

Osteoporosis

- ◆ Bisphosphonates
- ◆ Calcitonins

Miscellaneous

- ◆ Serotonin Receptor Agonists (Triptans)

In addition, the P&T Committee will review recently FDA-approved drugs in **Phase I** classes for PDL eligibility. If deemed PDL eligible, the Committee will determine the PDL status (preferred or non-preferred) of all drugs in these classes to be effective July 1, 2010 unless otherwise noted. Supplemental rebate offers are now being solicited for the following single source branded product:

- ◆ **Twynsta®** (*Angiotension II Receptor Blockers and Calcium Channel Blocker Combination*)

The following **potential new classes** will be reviewed at the February meeting, and if accepted by the P&T Committee, will be added to the PDL effective April 1, 2010 unless otherwise noted:

- ◆ **Insulins** including long-acting & rapid-acting insulin, insulin mixes, insulin 70/30, insulin N, insulin R
- ◆ **Injectable Hypoglycemic** agents including incretin enhancers/mimetics
- ◆ **Androgenic Agents** (effective date 7/1/10)
- ◆ **Platelet Inhibitors** (effective date 7/1/10)

The Department has set the following timeline for seeking supplemental rebates:


- **Friday, December 18, 2009:** Final supplemental rebate offers and the **signed Virginia Supplemental Drug Rebate Agreement** must be submitted to First Health by close of business.
- **Tuesday, February 9, 2010:** P&T Committee meets to review clinical information, pricing information, and to select which drugs will not require prior authorization.
- **Thursday, July 1, 2010:** Implement prior authorization requirements for drugs not selected as “preferred” on the PDL.

Questions regarding the PDL process should be sent to pdlinput@dmas.virginia.gov. All correspondence and inquiries regarding pricing and contracting should be directed to:

First Health Services Corporation
 Attention: Doug Brown, Rebate Contracting Manager
 4300 Cox Road
 Glen Allen, Virginia 23060
 Phone: 804-965-7695
 Email: DouglasBrown@firsthealth.com

We anticipate that future contracts with pharmaceutical manufacturers will make it possible for the Commonwealth to continue with its Virginia-specific approach. We look forward to working with you.

Sincerely,



Patrick W. Finnerty